Results 251 to 260 of about 112,049 (293)

Urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor-1

Oncology Reports, 1997
Tumor associated proteolysis is an essential mechanism in invasion and metastasis of cancer. The influence of the serine protease urokinase-like plasminogen activator (u-PA) and its inhibitor plasminogen activator inhibitor-1 (PAI-1) on the clinical prognosis of squamous carcinoma of the head and neck region (HNSCC) was evaluated. U-PA and PAI-1 levels
B, Wollenberg, N, Jan, R, Jund, S, Chaubal, M, Untch   +4 more
openaire   +2 more sources

Plasminogen Activators and Plasminogen Activator Inhibitor 1 in Urinary Tract Cancer

Urologia Internationalis, 1994
The plasminogen activation system is considered to play an important role in cancer growth and metastasis. Both plasminogen activators (PAs) and their fast-acting inhibitors are produced in tumor cells and their surrounding tissues. In order to clarify the influence of the existence of malignant tumor in urinary tract on the systemic fibrinolytic ...
H, Bashar, T, Urano, K, Fukuta, M H, Pietraszek, M, Hata, K, Suzuki, K, Kawabe, Y, Takada, A, Takada   +8 more
openaire   +2 more sources

Plasminogen Activator Inhibitor-1

2008
Fibrinolysis, the dissolution of fibrin clots, is an integral component of the hemostatic system that involves the concerted action of a complex system of zymogens, activators, and inhibitors [1]. Plasmin, the primary protease of the fibrinolysic system, digests fibrin, thereby converting insoluble clot to soluble fibrin degradation products.
Daniel T. Eitzman, William P. Fay, David Ginsburg   +2 more
openaire   +1 more source

Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Stroke Patients

Stroke, 1996
Background and Purpose Abnormal endogenous fibrinolytic activity may be a risk factor for stroke. Since the possible variation of tissue-type plasminogen activator (TPA) antigen and plasminogen activator inhibitor-1 (PAI-1) antigen concentrations over time after stroke has been rarely studied, it was examined in plasma from ...
A, Lindgren, C, Lindoff, B, Norrving, B, Astedt, B B, Johansson   +4 more
openaire   +2 more sources

Plasminogen activator inhibitor-1 modulates adipocyte differentiation

American Journal of Physiology-Endocrinology and Metabolism, 2006
Increased plasminogen activator inhibitor-1 (PAI-1) is linked to obesity and insulin resistance. However, the functional role of PAI-1 in adipocytes is unknown. This study was designed to investigate effects and underlying mechanisms of PAI-1 on glucose uptake in adipocytes and on adipocyte differentiation. Using primary cultured adipocytes from PAI-1+/
Xiubin, Liang, Talerngsak, Kanjanabuch, Su-Li, Mao, Chuan-Ming, Hao, Yi-Wei, Tang, Paul J, Declerck, Alyssa H, Hasty, David H, Wasserman, Agnes B, Fogo, Li-Jun, Ma   +9 more
openaire   +2 more sources

Plasminogen activator inhibitor‐1 and diabetic nephropathy

Nephrology, 2005
SUMMARY:  Diabetic nephropathy is characterized by excessive accumulation of extracellular matrix (ECM) in the kidney. Decreased ECM degradation as well as increased ECM synthesis plays an important role in ECM remodeling that favours tissue fibrosis. Plasminogen activator (PA)/plasmin/PA inhibitor (PAI) system is involved in ECM degradation and PAI‐1 ...
Hi Bahl, Lee, Hunjoo, Ha
openaire   +2 more sources

Plasminogen Activator Inhibitor-1 in Vascular Thrombosis

Current Drug Targets, 2007
Thrombotic complications of vascular disease constitute the leading cause of morbidity and mortality in much of the developed world. Current drug therapies available to treat the thrombotic component of arterial and venous vascular complications remain limited.
Randal J, Westrick, Daniel T, Eitzman
openaire   +2 more sources

Genetic Architecture of Tissue-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1

Seminars in Thrombosis and Hemostasis, 2008
Important biochemical constituents of the fibrinolytic system include tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). In the current review, we aim to describe the genetic architecture of t-PA and PAI-1. Several genetic polymorphisms in the T-PA and PAI-1 gene have been found to be associated with t-PA and PAI-1 ...
Asselbergs, Folkert W., Pattin, Kristine, Snieder, Harold, Hillege, Hans L., van Gilst, Wiek H., Moore, Jason H.   +5 more
openaire   +3 more sources

Neutralization by Plasminogen Activator Inhibitor-1 of Mutants of Tissue Plasminogen Activator

Enzyme, 1988
Deletion mutants of human tissue plasminogen activator (tPA) were expressed in Chinese hamster ovary cells. These cells had been transfected with genes that encoded tPA but included restriction sites that allowed the deletion of DNA encoding specific structural domains of the tPA molecule's heavy chain.
P W, Bergum, L A, Erickson
openaire   +2 more sources

Relation of plasminogen activator inhibitor-1 activity and plasminogen activator inhibitor-1 concentration in different plasma samples

Fibrinolysis, 1994
Abstract The relationship between PAI activity, active PAI-1 concentration and whole PAI-1 concentration was determined in 180 plasma samples of unselected ambulant patients of the department of internal medicine. To exclude a release of platelet PAI-1 after blood sampling, different anticoagulants and temperatures of blood storage were tested.
G. Siegert, Th. Fritz, E. Runge
openaire   +1 more source